Weifuchun tablets versus folic acid to reverse gastric intestinal metaplasia

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 4 interventional study enrolls adults aged 18–75 with OLGIM stage II–IV gastric intestinal metaplasia who are Helicobacter pylori–negative. Participants will take either Weifuchun tablets or folic acid every day for six months and visit the clinic about once every four weeks for exams and safety checks. Eligibility requires recent endoscopic and histopathologic confirmation of OLGIM stage II–IV, and investigators will compare changes in intestinal metaplasia and record any adverse events. Folic acid is used as the comparator in line with Chinese consensus recommendations for managing gastric precancerous conditions.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* patients aged from 18 to 75 years old.
* patients with OLGIM stage Ⅱ-Ⅳ diagnosed by upper gastrointestinal endoscopy and histopathological examination within the last 3 months.
* patients without Helicobacter pylori infection, including patients who had successful Helicobacter pylori eradication before enrollment.

Exclusion Criteria:

* a history of regular use (defined as at least once per week) of non-steroidal anti-inflammatory drugs (NSAIDs) and/or statins.
* a history of stomach surgery (including endoscopic submucosal dissection and endoscopic mucosal resection) or previously diagnosed malignant tumor.
* a history of heart failure, renal failure, liver cirrhosis or chronic hepatic failure; patients with contraindications or allergies to the drugs in this study.
* breastfeeding or pregnancy.
* a history of substance abuse or alcohol abuse within the past one year.
* patients with severe mental illness.
* refusal to undergo drug treatment.
* refusal to sign informed consent.

Where it's running

• Ankang Central Hospital
  Ankang, China Recruiting
• Tongchuan People's Hospital
  Tongchuan, China Recruiting
• Weinan Central Hospital
  Weinan, China Recruiting
• The 986th Hospital of Air Force Medical University
  Xi'an, China Recruiting
• Xijing hospital
  Xi'an, China Recruiting
• Xi'an Central Hospital
  Xi'an, China Recruiting

Study contacts

• Study coordinator: Yongquan Shi
• Email: shiyquan@fmmu.edu.cn
• Phone: 0086 + 02984771515

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• AI-assisted scoring for gastric IM using EGGIM shows how well doctors trained

  This trial tests whether AI-assisted EGGIM scoring helps endoscopists better identify gastric intestinal metaplasia in patients.

  Recruiting Qilu Hospital of Shandong University · Jinan, Shandong · NCT07208864

• Ursodeoxycholic acid for reversing gastric intestinal metaplasia

  This study will test whether taking ursodeoxycholic acid for six months can reverse gastric intestinal metaplasia in adults who do not have Helicobacter pylori infection.

  Recruiting at 6 sites Phase 4 Xijing Hospital of Digestive Diseases · Pingdingshan, Henan and 5 other locations · NCT06610760

• Reversing stomach intestinal metaplasia using pyrvinium

  This trial will test whether a two-week course of the drug pyrvinium can reduce or reverse high-risk gastric intestinal metaplasia in adults at increased risk for stomach cancer.

  Recruiting Phase 2 Duke University · Durham, North Carolina · NCT06590454

• Collecting health information to understand and prevent gastric cancer

  This study is trying to gather health information from people with early signs of gastric cancer, as well as healthy individuals and those already diagnosed, to better understand what might lead to this type of cancer.

  Recruiting at 7 sites Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT06370143

• Monitoring patients with precancerous stomach lesions

  This study is trying to find out how to better monitor people with precancerous stomach lesions to see who is at risk of developing gastric cancer and when they should come back for check-ups.

  Recruiting University of Latvia · Riga · NCT03250091

• Prevalence and possible role of non-H. pylori Helicobacter species in gastric conditions and cancers

  Researchers will test stomach tissue from people with functional dyspeasia, various gastritis conditions, gastric cancer, and bariatric patients to see if non-H. pylori Helicobacter species are present.

  Recruiting at 3 sites Universiteit Antwerpen · Edegem and 2 other locations · NCT07770126

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.